Business Plan Lonza Completes Expansion of Bioconjugation Facility
Lonza has successfully completed the expansion of its bioconjugation facility in Visp, Switzerland. The plant now includes two manufacturing suites along with supporting infrastructure which will help the firm to meet the growing demand for bioconjugates.
Basel/Switzerland – Lonza has recently announced that the planned expansion of its bioconjugation facility in Visp (CH) is now complete.
The expansion includes two manufacturing suites and supporting infrastructure. It will support an extended customer portfolio, including companies entering clinical development. The investment enhances Lonza’s capabilities and flexibility to support both clinical and commercial supply and will play a key role in meeting the growing market demand for bioconjugates.
The new suites complement Lonza’s recent investments and asset extensions in Visp (CH) in mammalian capacity, microbial development, drug product development and manufacturing, and HPAPI payload-linker manufacturing capacity. These continued investments into the Visp (CH) site provide a flexible solution for customers of all sizes at a single location. They are designed to help customers navigate the risks of a complex bioconjugation supply chain. In addition to the two new manufacturing suites, the expansion also includes an increase in process and analytical development and quality control capacity to support future portfolio growth.